Navigation Links
Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
Date:11/20/2013

-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, including risks related to the Company's ability to comply with the closing conditions or other conditions that might prevent the closing of the offering, the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioSpace Spotlights Northwests Life Science Community
2. Northwest Bio Implements Major Balance Sheet Clean-Up
3. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
4. Northwest Bio and Fraunhofer IZI Announce Milestones Reached
5. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
6. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
7. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
8. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
9. BioSpace Spotlights Northwests Life Science Community
10. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
11. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... MA (PRWEB) August 21, 2014 ... company, has been recognized as one of the ... | 5000 magazine for the 2nd consecutive year. ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ...
(Date:8/20/2014)... university inventions licensed to biotechnology firms has revealed ... open these roadblocks, the researchers suggest that better ... stage could lead to faster commercialization down the ... discoveries made in university laboratories and licensed to ... trials, which have a high failure rate. But ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Neurotrope To Host Conference Call 2
... HUBBARD, Ohio, April 8, 2008 NanoLogix, Inc.,(OTC ... 2007 financial data and a director appointment., ... were,reduced by 42% over 2006, while funding for ... information can be accessed at:, http://www.nanologixinc.com/financials.html , ...
... 8, 2008 Raven,biotechnologies, inc., a privately held ... antibody therapeutics (MAbs) for cancer,announced today that it ... under which Monogram will evaluate selected Raven,monoclonal antibodies ... cancer., "Raven,s extensive library of antibody candidates ...
... - The PerOs team is proud to announce,the ... the production,of bacterins as well as an autogenous ... (Oralject(TM))., "The approval of our manufacturing facility ... States marks a significant milestone for,our Company, and ...
Cached Biology Technology:NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director 2Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
(Date:8/21/2014)... a novel and versatile modeling strategy to simulate polyelectrolyte ... as well as for studying polyelectrolytes, including DNA and ... much larger and more complex polyelectrolyte systems, and to ... author of a paper on the work and a ... and Engineering. "This is a big step forward for ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell ... the March 2010 issue of Leukemia & Lymphoma. Traditionally ... Lymphoma has agreed to make this report available to the ... of the 2009 MCL Consortium Workshop. "It is gratifying ...
... Resistant wheat plants stave off attacks by Hessian fly larvae ... absorb nutrients, according to a study by Purdue University and ... - similar to human intestines - were observed in three ... function. Those that were given nothing to eat showed no ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Human PDGF R beta MAb (Clone # PR7212)...
... Ambion's ActivePro In Vitro ... an E.coli lysate, synthesizes ... as well as proteins ... than competing kits. This ...
Biology Products: